Aggregated price index with volume information
- Generic Drug Makers stocks down 1.6% on average while median return down 1.1% in a day
- Generic Drug Makers stocks up 1.7% on average while median return up 3.3% in a week
- Generic Drug Makers stocks down 6.4% on average while median return down -6.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $AMPH 25.0%, $COLL 19.1%, $TEVA 11.9%, $RDY 8.5%, $AMRX 7.7%
- 1M losers are : Losers for past month are $BHC -5.8%, $ANIP -23.6%, $CHRS -39.1%, $EGRX -58.5%, $ACRS -81.6%
- 1W winners are : Winners for past week are $ACRS 10.8%, $AMRX 9.0%, $AMPH 7.0%, $CHRS 4.3%, $BHC 3.9%
- 1W losers are : Losers for past week are $ANIP -0.7%, $EGRX -27.2%
Index correlation analysis
Correlation for the past month is 9.1%, for the past 3 months is 12.6%
In the past month for a 5 days rolling window, the highest corrrelation is 45.8%, the lowest correlation is 1.6%, the latest correlation is 10.3%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 69.0% between BHC and PRGO
The lowest correlation is -58.0% between ANIP and COLL
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitini
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders ...
Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
BRIDGEWATER, N.J., December 01, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") and Strides Pharma Science Limited ("Strides") today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023.
This biotech stock is in a base after the company produced triple-digit earnings growth. AMPH stock is poised for a move.
Here is how Bausch Health (BHC) and Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have performed compared to their sector so far this year.
PARSIPPANY, N.J., November 30, 2023--Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease.
Shirley Kuhlmann, the Executive Vice President and General Counsel of Collegium Pharmaceutical Inc, has recently sold 25,600 shares of the company's stock.
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.